Hyloris Board of Directors appoints Stijn Van Rompay as CEO

Reinforcement of Hyloris Governance

Liège, Belgium – 19 November 2025 – 07:00 AM CET – Regulated Information – Inside information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), the specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced an update on its governance and the Board of Directors' decision regarding the Hyloris' CEO position.

Stijn Van Rompay, currently co-CEO of Hyloris together with Thomas Jacobsen, co-CEO and Chief Business Development Officer, have been jointly leading the Company since the Hyloris' announcement of 8 July 2024, issued in the context of a forensic review initiated by the company itself.

Good Governance as a strength

Over the past months, Hyloris has engaged an external expert to carry out an in-depth review of its corporate governance. This assessment confirmed that good governance foundations were already in place at the time of review, including key policies such as the Communications Policy as announced by the company mid-2024, controls, and strategic oversight mechanisms. A significant amount of these expert recommendations has already been put into practice, and building further on this foundation, Hyloris is now formalizing and implementing the remaining measures to further reinforce its governance and internal control framework. Such includes the roll-out of comprehensive written compliance policies, approval flow for external written as well as oral regulated communication by the Board, its Chairman, and CLO or CFO, clarification of reporting structures, as well as enhancements to the Executive Committee, Board of Directors, Audit Committee, and the creation of a formal Product Selection Committee.

Full CEO responsibility to Stijn Van Rompay

Moreover, and following a thorough internal and external assessment of the current context, governance and compliance landscape, the Hyloris Board – based on the unanimous recommendation of the Independent Board members also representing the Remuneration and Nomination Committee - has decided to entrust full CEO responsibility to Stijn Van Rompay. The Board considers Stijn to be best positioned to lead Hyloris into its next stage of sustainable growth, with the full support of the Executive Committee and the entire Hyloris staff. With more than two decades of experience in the pharmaceutical industry, as founder, inspirational strategic leader, and co-architect of Hyloris' portfolio, Stijn brings deep operational and scientific insight, as well as team leadership and business acumen.

The Board also expressed a special thank you to Thomas Jacobsen, who will resume his previous responsibilities and focus fully on Business Development as Chief Business Development Officer, further advancing Hyloris' mission to innovate, reinvent and optimize existing medicines to address meaningful healthcare needs.

Governance and CEO driving sustainable Growth

Hyloris is determined to accelerate its momentum by combining its R&D excellence and partnering capabilities with the continued roll-out of its products in the United States and beyond. This combined focus aims to deliver sustainable growth and long-term value, while ensuring that Hyloris remains a transparent, accountable, and high-performing organization.

With clarity about the CEO position, Hyloris wants to ensure that its overall good governance framework, transparency, external communication and accountability across the organization, is fully aligned with best practices for a listed company and well positioned for its next stage of strategic growth in the interest of the company and its stakeholders.

About Hyloris Pharmaceuticals

Hyloris is the specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.

The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S or equivalent regulatory frameworks in other regions which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical burden required for market entry, and significantly shorten the development timelines, leading to reduced costs and risks.

Hyloris has built a broad development portfolio of 26 products, including 23 reformulated and/or repurposed value-added medicines that have the potential to offer significant advantages over existing alternatives. Two products are currently in early phases of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has 2 high barrier generic products approved in the U.S. and 1 high barrier generic product in development. Hyloris continuously evaluates additional product opportunities to drive future growth.

Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

For more information, contact Hyloris Pharmaceuticals:

Ann De Jaeger, CLO, legal representative of Impact WITH Empathy BV

Ann.dejaeger@hyloris.com

32 (0)475 20 13 44

Stijn Van Rompay, CEO, legal representative of SVR Management BV
stijn.vanrompay@hyloris.com

Thomas Jacobsen, CBDO, legal representative of Jacobsen Management BV
thomas.jacobsen@hyloris.com

32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares.

Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.